
Quicksome™: A Step Forward in Needle-Free Hormone Delivery
This morning we announced results from our exploratory human Quicksome™ testosterone study, and I am pleased to share why I believe this work represents an important step for the Company.
Registration is open for our 2026 Annual General Meeting
RegisterViewWe help biology perform better. Across agriculture and human health, our technologies address practical constraints that can limit crop productivity, molecule formulation and effective delivery.


Agriculture
Biological plant-signaling technology designed to support crop productivity, resilience and more efficient use of available inputs.
For growers, distributors and agricultural partners seeking measurable performance under real-world growing conditions.
Explore Agrarius™Human Health
Sublingual formulation and delivery technology for selected molecules limited by oral degradation, inconsistent absorption, injection or cold-chain requirements.
Solubility formulation technology for selected molecules limited by poor aqueous solubility.
For formulators, compound pharmacies, manufacturers and commercial partners seeking differentiated delivery and formulation solutions.
Explore Human Health
Press releases, company updates and coverage from across our human health and agriculture platforms.

This morning we announced results from our exploratory human Quicksome™ testosterone study, and I am pleased to share why I believe this work represents an important step for the Company.

Eight-participant pharmacokinetic study shows rapid systemic appearance following administration of 5 mg and 15 mg Quicksome™ sublingual formulations

Up to 32.5% more special-grade yield and 27.6% more total yield versus control. The independently designed and conducted Brazilian trial showed the strongest Agrarius program adding 8.0 tonnes per hectare in the higher-value 45 to 70 mm category, lifting special-grade share to about 80.7% of total yield versus 76.4% in the control.
Independent randomized field trial recorded numerical increases of up to 32.5% in special-grade potato yield and up to 27.6% in total yield in the leading Agrarius application programs.

The More Life Company (formerly MVMD), announces the completion of its corporate name change and is pleased to announce that its common shares will continue to be quoted on the OTCID under the new trading symbol “TMLCF”.

This morning, we announced the completion of our corporate name change from Mountain Valley MD to The More Life Company.

The More Life Company, formerly Mountain Valley MD Holdings Inc. (CSE: MVMD) (OTC: MVMDF), is pleased to announce that it has completed a corporate name change.

This morning we announced the appointment of five additional advisors to MVMD,

The Company has appointed the five individuals listed below as advisors to provide strategic advisory services to the Company.

Quicksome™ Technology and the Emerging Peptide Opportunity

Mountain Valley MD advances QuickSome™ sublingual delivery platform for compounded peptide applications, reports on initial formulation work across multiple peptides including BPC-157
